Story perspectives

Amivantamab Shows 76% Tumor Response in Cancer Trial

10/20/2025

29 6

Summary

Story summary

Amivantamab, a triple-action therapy, showed promising results for recurrent or metastatic head and neck squamous cell carcinoma and was presented at the European Society for Medical Oncology (ESMO) conference in Berlin.
The trial enrolled 86 patients, including Carl Walsh, who joined after other treatments failed.
Within six weeks, 76% experienced tumor shrinkage or stabilization.
Amivantamab works through three mechanisms, including blocking growth pathways and enhancing the immune response.

1 of 1

Story summary

Amivantamab, a triple-action therapy, showed promising results for recurrent or metastatic head and neck squamous cell carcinoma and was presented at the European Society for Medical Oncology (ESMO) conference in Berlin.
The trial enrolled 86 patients, including Carl Walsh, who joined after other treatments failed.
Within six weeks, 76% experienced tumor shrinkage or stabilization.
Amivantamab works through three mechanisms, including blocking growth pathways and enhancing the immune response.